JP4842829B2 - 含窒素縮合複素環化合物 - Google Patents

含窒素縮合複素環化合物 Download PDF

Info

Publication number
JP4842829B2
JP4842829B2 JP2006538217A JP2006538217A JP4842829B2 JP 4842829 B2 JP4842829 B2 JP 4842829B2 JP 2006538217 A JP2006538217 A JP 2006538217A JP 2006538217 A JP2006538217 A JP 2006538217A JP 4842829 B2 JP4842829 B2 JP 4842829B2
Authority
JP
Japan
Prior art keywords
compound
mmol
optionally substituted
reaction
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2006538217A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007510646A5 (https=
JP2007510646A (ja
Inventor
アルバート・チャールズ・ギョーコス
クリストファー・ピーター・コレット
スク・ヤン・チョー
ティモシー・マーク・ターナー
スコット・アラン・プラット
和義 麻生
郡  正城
倫代 業天
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical Co Ltd filed Critical Takeda Pharmaceutical Co Ltd
Publication of JP2007510646A publication Critical patent/JP2007510646A/ja
Publication of JP2007510646A5 publication Critical patent/JP2007510646A5/ja
Application granted granted Critical
Publication of JP4842829B2 publication Critical patent/JP4842829B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D235/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/30Nitrogen atoms not forming part of a nitro radical
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
JP2006538217A 2003-10-31 2004-10-27 含窒素縮合複素環化合物 Expired - Fee Related JP4842829B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US51616403P 2003-10-31 2003-10-31
US60/516,164 2003-10-31
US56051804P 2004-04-08 2004-04-08
US60/560,518 2004-04-08
PCT/US2004/035648 WO2005044793A2 (en) 2003-10-31 2004-10-27 Nitrogen-containing fused heterocyclic compounds

Publications (3)

Publication Number Publication Date
JP2007510646A JP2007510646A (ja) 2007-04-26
JP2007510646A5 JP2007510646A5 (https=) 2007-12-13
JP4842829B2 true JP4842829B2 (ja) 2011-12-21

Family

ID=34576771

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006538217A Expired - Fee Related JP4842829B2 (ja) 2003-10-31 2004-10-27 含窒素縮合複素環化合物

Country Status (5)

Country Link
US (1) US7714009B2 (https=)
EP (1) EP1677791A4 (https=)
JP (1) JP4842829B2 (https=)
CA (1) CA2543707A1 (https=)
WO (1) WO2005044793A2 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108970632A (zh) * 2018-08-14 2018-12-11 浙江辰阳化工有限公司 一种高效合成dbe的负载型双金属催化剂及其制备方法

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100376573C (zh) 2002-12-04 2008-03-26 卫材R&D管理有限公司 稠合的1,3-二氢-咪唑环化合物
US7429608B2 (en) 2005-01-20 2008-09-30 Amgen Inc. Benzo[d]imidazol analogs as vanilloid receptor ligands and their use in treatments
TWI370820B (en) * 2005-04-27 2012-08-21 Takeda Pharmaceutical Fused heterocyclic compounds
CA2612922A1 (en) 2005-06-21 2006-12-28 Neurosearch A/S 2-(phenylamino)benzimidazole derivatives and their use as modulators of small-conductance calcium-activated potassium channels
GB0515025D0 (en) * 2005-07-21 2005-08-31 Novartis Ag Organic compounds
US7547782B2 (en) 2005-09-30 2009-06-16 Bristol-Myers Squibb Company Met kinase inhibitors
GB0525068D0 (en) 2005-12-08 2006-01-18 Novartis Ag Organic compounds
WO2007069565A1 (ja) 2005-12-12 2007-06-21 Ono Pharmaceutical Co., Ltd. 二環式複素環化合物
CN101484433A (zh) 2006-02-15 2009-07-15 艾博特公司 新的乙酰辅酶a羧化酶(acc)抑制剂及其在糖尿病、肥胖症和代谢综合征中的应用
EP1996567B1 (en) 2006-02-15 2013-09-18 AbbVie Inc. Novel acetyl-coa carboxylase (acc) inhibitors and their use in diabetes, obesity and metabolic syndrome
JP2009526868A (ja) 2006-02-15 2009-07-23 アボット・ラボラトリーズ 新規なアセチル−CoAカルボキシラーゼ(ACC)阻害薬およびこれらの糖尿病、肥満および代謝症候群における使用
FR2903107B1 (fr) 2006-07-03 2008-08-22 Sanofi Aventis Sa Derives d'imidazopyridine-2-carboxamides, leur preparation et leur application en therapeutique
FR2903105A1 (fr) * 2006-07-03 2008-01-04 Sanofi Aventis Sa Derives de 2-benzoyl-imidazopyridines, leur preparation et leur application en therapeutique
US20100056515A1 (en) * 2006-10-25 2010-03-04 Kazuyoshi Aso Benzimidazole compounds
JP2010514672A (ja) * 2006-12-29 2010-05-06 武田薬品工業株式会社 Crfアンタゴニスト活性を有する縮合複素環化合物
DE102008023801A1 (de) 2008-05-15 2009-11-19 Bayer Schering Pharma Aktiengesellschaft Substituierte Imidazo- und Triazolopyrimidine, Imidazo- und Pyrazolopyrazine und Imidazotriazine
WO2010032461A1 (ja) * 2008-09-17 2010-03-25 武田薬品工業株式会社 含窒素縮合環化合物
UY32138A (es) 2008-09-25 2010-04-30 Boehringer Ingelheim Int Amidas sustituidas del ácido 2-(2,6-dicloro-fenilamino)-6-fluoro-1-metil-1h-bencimidazol-5-carboxílico y sus sales farmacéuticamente aceptables
US8394969B2 (en) 2008-09-26 2013-03-12 Merck Sharp & Dohme Corp. Cyclic benzimidazole derivatives useful as anti-diabetic agents
EP2348857B1 (en) 2008-10-22 2016-02-24 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
EP2352374B1 (en) 2008-10-29 2014-09-24 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
US8329914B2 (en) 2008-10-31 2012-12-11 Merck Sharp & Dohme Corp Cyclic benzimidazole derivatives useful as anti-diabetic agents
US8349852B2 (en) 2009-01-13 2013-01-08 Novartis Ag Quinazolinone derivatives useful as vanilloid antagonists
UY32470A (es) 2009-03-05 2010-10-29 Boehringer Ingelheim Int Derivados de 2-{2-cloro-5-[(sustituido) metil]fenilamino} -1-metil]fenilamino}-1-metilbencimidazol-5-carboxamidas-n-(sustituidas) y sus sales fisiológicamente aceptables, composiciones conteniéndolos y aplicaciones
JP2013518085A (ja) 2010-02-01 2013-05-20 ノバルティス アーゲー CRF−1受容体アンタゴニストとしてのピラゾロ[5,1b]オキサゾール誘導体
AR080056A1 (es) 2010-02-01 2012-03-07 Novartis Ag Derivados de ciclohexil-amida como antagonistas de los receptores de crf
JP5748777B2 (ja) 2010-02-02 2015-07-15 ノバルティス アーゲー Crf受容体アンタゴニストとしてのシクロヘキシルアミド誘導体
CN102153538B (zh) * 2010-02-11 2013-12-11 山东轩竹医药科技有限公司 苯并环衍生物
JP2013520502A (ja) 2010-02-25 2013-06-06 メルク・シャープ・エンド・ドーム・コーポレイション 有用な抗糖尿病薬である新規な環状ベンズイミダゾール誘導体
US8586604B2 (en) 2010-08-20 2013-11-19 Boehringer Ingelheim International Gmbh Inhibitors of the microsomal prostaglandin E2 synthase-1
US8759537B2 (en) 2010-08-20 2014-06-24 Boehringer Ingelheim International Gmbh 3H-imidazo [4, 5-C] pyridine-6-carboxamides as anti-inflammatory agents
TW201217387A (en) 2010-09-15 2012-05-01 Hoffmann La Roche Azabenzothiazole compounds, compositions and methods of use
RU2632900C2 (ru) 2010-11-19 2017-10-11 Лиганд Фармасьютикалс Инкорпорейтед Гетероциклические амины и их применение
US8486968B2 (en) 2010-12-10 2013-07-16 Boehringer Ingelheim International Gmbh Compounds
US8466186B2 (en) 2010-12-10 2013-06-18 Boehringer Ingelheim International Gmbh Compounds
UY33779A (es) 2010-12-10 2012-07-31 Boehringer Ingelheim Int ?2-(fenilamino)-1H-bencimidazol-5-carboxamidas novedosas?
UY34094A (es) 2011-05-27 2013-01-03 Novartis Ag Derivados de la piperidina 3-espirocíclica como agonistas de receptores de la ghrelina
CA2867043A1 (en) 2012-05-03 2013-11-07 Novartis Ag L-malate salt of 2,7-diaza-spiro[4.5]dec-7-yle derivatives and crystalline forms thereof as ghrelin receptor agonists
EA031655B1 (ru) 2014-02-11 2019-02-28 Байер Фарма Акциенгезельшафт Бензимидазол-2-амины в качестве ингибиторов midhi
US9951027B2 (en) 2014-02-11 2018-04-24 Bayer Pharma Aktiengesellschaft Benzimidazol-2-amines as MIDH1 inhibitors
US9527835B2 (en) 2014-02-13 2016-12-27 Incyte Corporation Cyclopropylamines as LSD1 inhibitors
EP3105218B1 (en) 2014-02-13 2019-09-25 Incyte Corporation Cyclopropylamines as lsd1 inhibitors
EP3105219B9 (en) 2014-02-13 2018-10-03 Incyte Corporation Cyclopropylamines as lsd1 inhibitors
JP6602779B2 (ja) 2014-02-13 2019-11-06 インサイト・コーポレイション Lsd1阻害剤としてのシクロプロピルアミン類
EP3134405B1 (en) 2014-04-25 2019-08-28 Pfizer Inc Heteroaromatic compounds and their use as dopamine d1 ligands
US9758523B2 (en) 2014-07-10 2017-09-12 Incyte Corporation Triazolopyridines and triazolopyrazines as LSD1 inhibitors
WO2016007731A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Imidazopyridines and imidazopyrazines as lsd1 inhibitors
US9695180B2 (en) 2014-07-10 2017-07-04 Incyte Corporation Substituted imidazo[1,2-a]pyrazines as LSD1 inhibitors
US9695167B2 (en) 2014-07-10 2017-07-04 Incyte Corporation Substituted triazolo[1,5-a]pyridines and triazolo[1,5-a]pyrazines as LSD1 inhibitors
JP6672288B2 (ja) 2014-10-23 2020-03-25 バイエル・ファルマ・アクティエンゲゼルシャフト 腫瘍の治療のためのmidh1阻害剤としての1−シクロヘキシル−2−フェニルアミノベンゾイミダゾール
WO2016062677A1 (en) 2014-10-23 2016-04-28 Bayer Pharma Aktiengesellschaft Benzimidazol-2-amines as midh1 inhibitors
EP3277689B1 (en) 2015-04-03 2019-09-04 Incyte Corporation Heterocyclic compounds as lsd1 inhibitors
EP3303302B1 (en) 2015-06-08 2019-03-20 Bayer Pharma Aktiengesellschaft N-menthylbenzimidazoles as midh1 inhibitors
JP6824954B2 (ja) 2015-07-16 2021-02-03 ドイチェス クレープスフォルシュングスツェントルム シュティフトゥング デス エッフェントリッヒェン レヒツ mIDH1阻害剤としての5−ヒドロキシアルキルベンズイミダゾール
MY189367A (en) 2015-08-12 2022-02-08 Incyte Corp Salts of an lsd1 inhibitor
TWI833686B (zh) 2016-04-22 2024-03-01 美商英塞特公司 Lsd1 抑制劑之調配物
US10968200B2 (en) 2018-08-31 2021-04-06 Incyte Corporation Salts of an LSD1 inhibitor and processes for preparing the same
CN110156712A (zh) * 2019-04-25 2019-08-23 邵玉田 一种利用芳烃硝化副产物合成苯并恶唑类化合物及应用
WO2024211836A2 (en) 2023-04-05 2024-10-10 Moma Therapeutics, Inc. Semi-saturated bicyclic derivatives and related uses
TW202530189A (zh) 2023-09-29 2025-08-01 日商第一三共股份有限公司 3-苯基丙基胺衍生物

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003043636A1 (en) * 2001-11-19 2003-05-30 F. Hoffmann-La Roche Ag Nicotin-or isonicotin benzothiazole derivatives
WO2003053946A1 (en) * 2001-12-12 2003-07-03 F. Hoffmann-La Roche Ag 7-amino-benzothiazole derivatives as adenosine receptor ligands
JP2003528802A (ja) * 1999-04-02 2003-09-30 ニューロゲン コーポレイション N−ベンゾイミダゾリルメチル−及びn−インドリルメチル−ベンズアミド並びにcrf調節物質としてのそれらの使用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH653021A5 (fr) 1981-04-24 1985-12-13 Delalande Sa Derives piperidino, piperazino et homopiperazino, n-substitues par un groupe heterocyclique aromatique, leur procede de preparation et composition therapeutique les contenant.
AU577802B2 (en) 1983-10-17 1988-10-06 Duphar International Research B.V. Blood-pressure lowering piperazine derivatives
DE4241658A1 (de) 1992-12-04 1994-06-09 Schering Ag Substituierte 2-Thiobenzthiazole, Verfahren zu ihrer Herstellung und ihre Verwendung als herbizide Mittel
BR9407799A (pt) * 1993-10-12 1997-05-06 Du Pont Merck Pharma Composição de matéria método de tratamento e composição farmaceutica
US6077812A (en) 1997-02-26 2000-06-20 Fmc Corporation Cycloimido-substituted benzofused heterocyclic herbicides
US6281237B1 (en) * 1999-04-02 2001-08-28 Neurogen Corporation N-phenyl benzimidazolecarboxamide and N-phenyl indolecarboxamide derivatives
MY125533A (en) 1999-12-06 2006-08-30 Bristol Myers Squibb Co Heterocyclic dihydropyrimidine compounds
AR028385A1 (es) 2000-04-28 2003-05-07 Acadia Pharm Inc Agonistas muscarinicos
EP1301483A1 (de) 2000-07-18 2003-04-16 Basf Aktiengesellschaft 1-aryl-4-halogenalkyl-2-(1h)-pyridone und ihre verwendung als herbizide
TWI312347B (en) 2001-02-08 2009-07-21 Eisai R&D Man Co Ltd Bicyclic nitrogen-containing condensed ring compounds
US6599901B1 (en) 2001-11-19 2003-07-29 Hoffman-La Roche Inc. Pyridone substituted benzothiazole derivatives
US6596718B1 (en) 2001-11-27 2003-07-22 Hoffmann-La Roche Inc. 7-Morpholin-4yl-benzothiazole amide derivatives
US6624163B2 (en) 2001-11-29 2003-09-23 Hoffman-La Roche Inc. Benzothiazole derivatives
US6727247B2 (en) 2001-12-10 2004-04-27 Hoffman-La Roche Inc. Substituted benzothiazole amide derivatives
US7087761B2 (en) 2003-01-07 2006-08-08 Hoffmann-La Roche Inc. Cyclization process for substituted benzothiazole derivatives
FR2851563B1 (fr) * 2003-02-26 2005-04-22 Sod Conseils Rech Applic Nouveaux derives de benzimidazole et d'imidazo-pyridine et leur utilisation en tant que medicament
US7531553B2 (en) * 2003-03-21 2009-05-12 Amgen Inc. Heterocyclic compounds and methods of use

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003528802A (ja) * 1999-04-02 2003-09-30 ニューロゲン コーポレイション N−ベンゾイミダゾリルメチル−及びn−インドリルメチル−ベンズアミド並びにcrf調節物質としてのそれらの使用
WO2003043636A1 (en) * 2001-11-19 2003-05-30 F. Hoffmann-La Roche Ag Nicotin-or isonicotin benzothiazole derivatives
WO2003053946A1 (en) * 2001-12-12 2003-07-03 F. Hoffmann-La Roche Ag 7-amino-benzothiazole derivatives as adenosine receptor ligands

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108970632A (zh) * 2018-08-14 2018-12-11 浙江辰阳化工有限公司 一种高效合成dbe的负载型双金属催化剂及其制备方法

Also Published As

Publication number Publication date
WO2005044793A2 (en) 2005-05-19
JP2007510646A (ja) 2007-04-26
EP1677791A4 (en) 2007-08-15
CA2543707A1 (en) 2005-05-19
US20070135452A1 (en) 2007-06-14
US7714009B2 (en) 2010-05-11
WO2005044793A3 (en) 2006-03-30
EP1677791A2 (en) 2006-07-12

Similar Documents

Publication Publication Date Title
JP4842829B2 (ja) 含窒素縮合複素環化合物
US8703794B2 (en) Indazole inhibitors of the Wnt signal pathway and therapeutic uses thereof
EP0268989B1 (en) Imidazopyridine compounds and processes for preparation thereof
EP1925617B1 (en) Heterocyclic compound, and production process and use thereof
JP4790703B2 (ja) 環式化合物
JP4145492B2 (ja) テトラヒドロピリドエーテル
EP2998296B1 (en) Cycloalkyl acid derivative, preparation method thereof, and pharmaceutical application thereof
CA2598639A1 (en) Hydroxyalkyl substituted imidazonaphthyridines
EP1474425A1 (en) Deazapurines and uses thereof
KR20030019555A (ko) 프로판-1,3-디온 유도체
JPH07502742A (ja) Paf−レセプタ拮抗剤としてのアミノ酸誘導体
CA2922077A1 (en) Quinoline-substituted compound
HU196971B (en) Process for producing new benzimidazol derivatives and pharmaceutical compositions containing them
MX2007013154A (es) Compuestos heterociclicos fusionados.
HUT67312A (en) Naphtalene derivatives and process for their producing
EP2861578A1 (en) Compounds and compositions for modulating egfr activity
US4782055A (en) Imidazopyridine compounds useful in the treatment of ulcers
EP0404797B1 (en) 1H/3H-[4-(N,N-CYCLOALKYL AND/OR BRANCHED-ALKYLCARBOXAMIDO) -BENZYL]IMIDAZO[4,5-c]PYRIDINES AS PAF ANTAGONISTS
JPWO1992012144A1 (ja) ベンゾオキサ縮合環化合物
JP2010514672A (ja) Crfアンタゴニスト活性を有する縮合複素環化合物
JPH07133224A (ja) 動脈硬化治療薬
JPH05222000A (ja) ベンズイミダゾール誘導体およびその製造方法
JP3951395B2 (ja) ピリジン誘導体、その製法及びその合成中間体
BG100209A (bg) Пиролохинолинонови производни с позитивна инотропна и лузитропна активност
JP2005239611A (ja) ピラゾロピリミジン誘導体およびその用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20071026

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20071026

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110301

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110425

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20110524

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110823

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20110901

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20110927

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20111006

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20141014

Year of fee payment: 3

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20141014

Year of fee payment: 3

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20141014

Year of fee payment: 3

LAPS Cancellation because of no payment of annual fees